Keyphrases
Clinical Trials
89%
Olaparib
53%
Core Outcome Set
53%
Risk-benefit
36%
Patient Outcomes
30%
Objective Response Rate
30%
Risk Outcomes
26%
Selinexor
26%
Solid Malignancies
26%
Patient Benefit
26%
Drug Development
26%
Patient Risk
26%
Lung Cancer
26%
Reporting Guidelines
26%
Chronic Kidney Disease
26%
Web-based Survey
26%
Clinical Neurology
26%
Clinical Perspective
26%
Clinical Trial Registry
22%
Adverse Events
20%
Overall Survival
20%
Progression-free Survival
16%
Control Arm
16%
New Indication
13%
Drug Manufacturer
13%
Ovarian Cancer
13%
Health Research
13%
Trial Characteristics
11%
PubMed
10%
Median Progression-free Survival
10%
Cochrane
10%
Embase
10%
MEDLINE
10%
Requirements Selection
8%
Consolidated Standards of Reporting Trials (CONSORT)
8%
Top 100
8%
Cancer Clinical Trials
8%
Capital Investment
6%
Time Investment
6%
Pooled Analysis
6%
Mutation Characteristics
6%
Therapy Options
6%
Safety Criteria
6%
Novel Chemotherapy
6%
Drug Efficacy
6%
Adverse Event Rates
6%
Oncologic
6%
Solid Cancer
6%
Oncology
6%
Complete Response
6%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Olaparib
53%
Lung Cancer
26%
Chronic Kidney Failure
26%
Drug Development
26%
Selinexor
26%
Adverse Event
26%
Progression Free Survival
26%
Malignant Neoplasm
20%
Overall Survival
20%
Ovary Cancer
13%
Pharmaceutical Manufacturing
13%
Prevalence
6%
Multiple Myeloma
6%
Chemotherapy
6%
Solid Malignant Neoplasm
6%
Medicine and Dentistry
Clinical Trial
100%
Olaparib
53%
Lung Cancer
26%
Clinical Neurology
26%
Chronic Kidney Disease
26%
Malignant Neoplasm
20%
Clinician
17%
Ovarian Cancer
13%
Adverse Event
13%
Progression Free Survival
13%
Medicine
10%
Randomized Controlled Trial
8%
Pooled Analysis
6%
Prevalence
6%
Outcome Assessment
6%
Cancer Research
6%
Drug Therapy
6%
Oncology
6%
Drug Efficacy
6%
Overall Survival
6%
Lifespan
6%
Solid Malignant Neoplasm
6%
Systematic Review
5%
